Metraipolis › archive › dc_5fe36abbf5f1

Derivation and external validation of a risk score for predicting HIV-associated tuberculosis to support case finding and preventive therapy scale-up: A… — Europe PMC PMID:34491987

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/34491987
DOI
10.1371/journal.pmed.1003739
License (as archived)
CC0-1.0
Archived
2026-11-03T00:17:41.580Z
SHA-256 of the archived text
74a042c8daa7347222afdd0be5ec014ee98b2dfd25ead82d9be6811961e75141
Stable URL of this page
https://metraipolis.com/documento/dc_5fe36abbf5f1

How to cite

Derivation and external validation of a risk score for predicting HIV-associated tuberculosis to support case finding and preventive therapy scale-up: A… — Europe PMC PMID:34491987 — Europe PMC (en), https://europepmc.org/article/MED/34491987 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_5fe36abbf5f1 (Metraipolis archive dc_5fe36abbf5f1, sha256 74a042c8daa7347222afdd0be5ec014ee98b2dfd25ead82d9be6811961e75141)
BibTeX
@misc{dc5fe36abbf5f1,
  title = {Derivation and external validation of a risk score for predicting HIV-associated tuberculosis to support case finding and preventive therapy scale-up: A… — Europe PMC PMID:34491987},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34491987},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_5fe36abbf5f1; sha256 74a042c8daa7347222afdd0be5ec014ee98b2dfd25ead82d9be6811961e75141},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34491987. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Among people living with HIV (PLHIV), more flexible and sensitive tuberculosis (TB) screening tools capable of detecting both symptomatic and subclinical active TB are needed to (1) reduce morbidity and mortality from undiagnosed TB; (2) facilitate scale-up of tuberculosis preventive therapy (TPT) while reducing inappropriate prescription of TPT to PLHIV with subclinical active TB; and (3) allow for differentiated HIV-TB care. Methods and findings: We used Botswana XPRES trial data for adult HIV clinic enrollees collected during 2012 to 2015 to develop a parsimonious multivariable prognostic model for active prevalent TB using both logistic regression and random forest machine learning approaches. A clinical score was derived by rescaling final model coefficients. The clinical score was developed using southern Botswana XPRES data and its accuracy validated internally, using northern Botswana data, and externally using 3 diverse cohorts of antiretroviral therapy (ART)-naive and ART-experienced PLHIV enrolled in XPHACTOR, TB Fast Track (TBFT), and Gugulethu studies from South Africa (SA). Predictive accuracy of the clinical score was compared with the World Health Organization (WHO) 4-symptom TB screen. Among 5,418 XPRES enrollees, 2,771 were included in the derivation dataset; 67% were female, median age was 34 years, median CD4 was 240 cells/μL, 189 (7%) had undiagnosed prevalent TB, and characteristics were similar between internal derivation and validation datasets. Among XPHACTOR, TBFT, and Gugulethu cohorts, median CD4 was 400, 73, and 167 cells/μL, and prevalence of TB was 5%, 10%, and 18%, respectively. Factors predictive of TB in the derivation dataset and selected for the clinical score included male sex (1 point), ≥1 WHO TB symptom (7 points), smoking history (1 point), temperature >37.5°C (6 points), body mass index (BMI) 10) yielded TB prevalence of 1%, 1%, 2%, and 6% in the lowest risk group and 33%, 22%, 26%, and 32% in the highest risk group for XPRES, XPHACTOR, TBFT, and Gugulethu cohorts, respectively. At clinical score ≥2, the number needed to screen (NNS) ranged from 5.0 in Gugulethu to 11.0 in XPHACTOR. Limitations include that the risk score has not been validated in resource-rich settings and needs further evaluation and validation in contemporary cohorts in Africa and other resource-constrained settings. Conclusions: The simple and feasible clinical score allowed for prioritization of sensitivity and NPV, which could facilitate reductions in mortality from undiagnosed TB and safer administration of TPT during proposed global scale-up efforts. Differentiation of risk by clinical score cutoff allows flexibility in designing differentiated HIV-TB care to maximize impact of available resources.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS medicine, 2021 (prima pubblicazione 2021-09-07).
Identificativi: PMID 34491987 · PMCID PMC8454974 · DOI 10.1371/journal.pmed.1003739.
Descrittori MeSH principali: Mass Screening; HIV Long-Term Survivors; Preventive Health Services; Coinfection.
Pagina: https://europepmc.org/article/MED/34491987 — https://doi.org/10.1371/journal.pmed.1003739. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-03T00:12:33.286Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.